Gubra Secures $350M to Accelerate Next-Gen Therapeutics in Metabolic Health

Gubra is thrilled to announce the successful raise of 350,000,000 in funding, a milestone that marks a significant step forward in our mission to advance cutting‐edge research within the metabolic space. Founded in 2008, we have built a reputation as a pioneering biotech company specializing in two primary areas: preclinical contract research organization (CRO) services and proprietary early target and drug discovery programs. Our scientific endeavors focus on complex metabolic diseases including obesity, diabetes, MASH, and gastrointestinal disorders, where our expertise in peptide chemistry, in vivo pharmacology, ex vivo assays, molecular pharmacology, histology, imaging, stereology, next generation sequencing (NGS), and bioinformatics has set us apart in the field. The new capital will be focused on accelerating our research capabilities, enhancing our state-of-the-art laboratories, and broadening our portfolio of innovative therapeutic targets. We plan to further invest in our core competencies and expand collaborations with global partners in the pharmaceutical and biotech industries, as well as leading academic institutions. As our name suggests—an abbreviation of GUt and BRAin—we remain committed to merging cutting-edge biological research with innovative scientific approaches. This strategic funding will not only propel our proprietary drug discovery programs forward but also reinforce our commitment to delivering high-quality services and breakthrough solutions that meet the evolving needs of our diverse clientele. At Gubra, we are excited about the opportunities this funding provides and look forward to deepening our contributions to the scientific community while ultimately improving patient outcomes worldwide.